{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:43:27Z","timestamp":1793036607685,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04182-6","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:07:42Z","timestamp":1767629262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Construction and external validation of a prognostic model for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization: a multicenter retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Fangyi","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanning","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"4","key":"4182_CR1","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/j.jhep.2022.12.002","volume":"78","author":"C Li","year":"2023","unstructured":"Li C, He W-Q. Global prediction of primary liver cancer incidences and mortality in 2040. J Hepatol. 2023;78(4):e144\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.002.","journal-title":"J Hepatol"},{"issue":"6","key":"4182_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"issue":"12","key":"4182_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864\u201384. https:\/\/doi.org\/10.1038\/s41571-023-00825-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"4182_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2174\/0109298665330781240830042601","volume":"31","author":"W Ye","year":"2024","unstructured":"Ye W, Wang J, Zheng J, Jiang M, Zhou Y, Wu Z. Association between higher expression of Vav1 in hepatocellular carcinoma and unfavourable clinicopathological features and prognosis. Protein Pept Lett. 2024;31(9):706\u201313. https:\/\/doi.org\/10.2174\/0109298665330781240830042601.","journal-title":"Protein Pept Lett"},{"issue":"5","key":"4182_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/1566523222666220825110147","volume":"24","author":"C Liu","year":"2024","unstructured":"Liu C, Shi J, Lin B, Zhou M, Shan D, Nie J, et al. SHR6390 combined with cabozantinib inhibits tumor progression in the hepatocellular carcinoma mouse model. Curr Gene Ther. 2024;24(5):453\u201364. https:\/\/doi.org\/10.2174\/1566523222666220825110147.","journal-title":"Curr Gene Ther"},{"issue":"3","key":"4182_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/0115665232274223231017052707","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, Sun L, Liu Y, Zhang Y. FIGNL1 promotes hepatocellular carcinoma formation via remodeling ECM-receptor interaction pathway mediated by HMMR. Curr Gene Ther. 2024;24(3):249\u201363. https:\/\/doi.org\/10.2174\/0115665232274223231017052707.","journal-title":"Curr Gene Ther"},{"issue":"1","key":"4182_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/0113892029308243240709073945","volume":"26","author":"IP Gudivada","year":"2025","unstructured":"Gudivada IP, Amajala KC. Integrative bioinformatics analysis for targeting hub genes in hepatocellular carcinoma treatment. Curr Genomics. 2025;26(1):48\u201380. https:\/\/doi.org\/10.2174\/0113892029308243240709073945.","journal-title":"Curr Genomics"},{"issue":"3","key":"4182_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"10126","key":"4182_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(18)30207-1.","journal-title":"Lancet"},{"key":"4182_CR10","doi-asserted-by":"publisher","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","volume":"29","author":"A Vogel","year":"2018","unstructured":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238\u201355. https:\/\/doi.org\/10.1093\/annonc\/mdy308.","journal-title":"Ann Oncol"},{"issue":"8","key":"4182_CR11","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1007\/s00464-019-06781-3","volume":"33","author":"M Xiangfei","year":"2019","unstructured":"Xiangfei M, Yinzhe X, Yingwei P, Shichun L, Weidong D. Open versus laparoscopic hepatic resection for hepatocellular carcinoma: a systematic review and meta-analysis. Surg Endosc. 2019;33(8):2396\u2013418. https:\/\/doi.org\/10.1007\/s00464-019-06781-3.","journal-title":"Surg Endosc"},{"issue":"4","key":"4182_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ajg.2011.425","volume":"107","author":"S Shiina","year":"2012","unstructured":"Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569\u201377. https:\/\/doi.org\/10.1038\/ajg.2011.425.","journal-title":"Am J Gastroenterol"},{"key":"4182_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218165","author":"Y Chang","year":"2020","unstructured":"Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21218165.","journal-title":"Int J Mol Sci"},{"key":"4182_CR14","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.2019180021","author":"A Morshid","year":"2019","unstructured":"Morshid A, Elsayes KM, Khalaf AM, Elmohr MM, Yu J, Kaseb AO, et al. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiology: Artificial Intelligence. 2019. https:\/\/doi.org\/10.1148\/ryai.2019180021.","journal-title":"Radiology: Artificial Intelligence"},{"key":"4182_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41068-7","author":"S-Y Ho","year":"2023","unstructured":"Ho S-Y, Liu P-H, Hsu C-Y, Huang Y-H, Lei H-J, Liao J-I, et al. Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-41068-7.","journal-title":"Sci Rep"},{"issue":"000","key":"4182_CR16","doi-asserted-by":"publisher","first-page":"000","DOI":"10.14218\/jcth.2022.00293","volume":"000","author":"B-Y Zhong","year":"2022","unstructured":"Zhong B-Y, Jin Z-C, Chen J-J, Zhu H-D, Zhu X-L. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol. 2022;000(000):000. https:\/\/doi.org\/10.14218\/jcth.2022.00293.","journal-title":"J Clin Transl Hepatol"},{"key":"4182_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030436","author":"E Kotsifa","year":"2022","unstructured":"Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, et al. Transarterial chemoembolization for hepatocellular carcinoma: why, when, how? J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12030436.","journal-title":"J Pers Med"},{"key":"4182_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02387-7","author":"J Ji","year":"2022","unstructured":"Ji J, Yang W, Shi H-B, Liu S, Zhou W-Z. Transcatheter arterial chemoembolization alone versus combined with microwave ablation for recurrent small hepatocellular carcinoma after resection: a retrospective comparative study. BMC Gastroenterol. 2022. https:\/\/doi.org\/10.1186\/s12876-022-02387-7.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"4182_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2017","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017;67(1):358\u201380. https:\/\/doi.org\/10.1002\/hep.29086.","journal-title":"Hepatology"},{"key":"4182_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132430","author":"EL Fite","year":"2024","unstructured":"Fite EL, Makary MS. Transarterial chemoembolization treatment paradigms for hepatocellular carcinoma. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16132430.","journal-title":"Cancers"},{"key":"4182_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14050514","author":"A Zamanian","year":"2024","unstructured":"Zamanian A, von Kleist H, Ciora O-A, Piperno M, Lancho G, Ahmidi N. Analysis of missingness scenarios for observational health data. J Pers Med. 2024. https:\/\/doi.org\/10.3390\/jpm14050514.","journal-title":"J Pers Med"},{"key":"4182_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/jhc.S271498","volume":"7","author":"W Xu","year":"2020","unstructured":"Xu W, Liu F, Shen X, Li R. Prognostic nomograms for patients with hepatocellular carcinoma after curative hepatectomy, with a focus on recurrence timing and post-recurrence management<\/p> J Hepatocell Carcinoma. 2020;7:233\u201356. https:\/\/doi.org\/10.2147\/jhc.S271498.","journal-title":"J Hepatocell Carcinoma"},{"key":"4182_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01375-x","author":"KL Pickett","year":"2021","unstructured":"Pickett KL, Suresh K, Campbell KR, Davis S, Juarez-Colunga E. Random survival forests for dynamic predictions of a time-to-event outcome using a longitudinal biomarker. BMC Med Res Methodol. 2021. https:\/\/doi.org\/10.1186\/s12874-021-01375-x.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"4182_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jhep.2015.01.033","volume":"62","author":"A Facciorusso","year":"2015","unstructured":"Facciorusso A, Bhoori S, Sposito C, Mazzaferro V. Repeated transarterial chemoembolization: an overfitting effort? J Hepatol. 2015;62(6):1440\u20132. https:\/\/doi.org\/10.1016\/j.jhep.2015.01.033.","journal-title":"J Hepatol"},{"key":"4182_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1354964","author":"HL Lee","year":"2024","unstructured":"Lee HL, Kim SH, Kim HY, Lee SW, Song MJ. A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1354964.","journal-title":"Front Oncol"},{"issue":"8","key":"4182_CR26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2174\/1386207326666230824090204","volume":"27","author":"J Tao","year":"2024","unstructured":"Tao J, Shi X, Feng X, Wu X, Qi S, Feng G, et al. Development and validation of a risk prediction algorithm for evaluating the efficacy of postoperative adjuvant TACE therapy for hepatocellular carcinoma. Comb Chem High Throughput Screen. 2024;27(8):1111\u20138. https:\/\/doi.org\/10.2174\/1386207326666230824090204.","journal-title":"Comb Chem High Throughput Screen"},{"key":"4182_CR27","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.2147\/jhc.S481301","volume":"11","author":"M Zhou","year":"2024","unstructured":"Zhou M, Zhang P, Mao Q, Shi Y, Yang L, Zhang X. Multisequence MRI-based radiomic features combined with inflammatory indices for predicting the overall survival of HCC patients after TACE. J Hepatocell Carcinoma. 2024;11:2049\u201361. https:\/\/doi.org\/10.2147\/jhc.S481301.","journal-title":"J Hepatocell Carcinoma"},{"issue":"17","key":"4182_CR28","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.1088\/0031-9155\/61\/17\/6553","volume":"61","author":"DF Polan","year":"2016","unstructured":"Polan DF, Brady SL, Kaufman RA. Tissue segmentation of computed tomography images using a random forest algorithm: a feasibility study. Phys Med Biol. 2016;61(17):6553\u201369. https:\/\/doi.org\/10.1088\/0031-9155\/61\/17\/6553.","journal-title":"Phys Med Biol"},{"key":"4182_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.608260","author":"H Lin","year":"2021","unstructured":"Lin H, Zeng L, Yang J, Hu W, Zhu Y. A machine learning-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.608260.","journal-title":"Front Oncol"},{"key":"4182_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15030252","author":"M Romeo","year":"2025","unstructured":"Romeo M, Dallio M, Napolitano C, Basile C, Di Nardo F, Vaia P, et al. Clinical applications of artificial intelligence (AI) in human cancer: is it time to update the diagnostic and predictive models in managing hepatocellular carcinoma (HCC)? Diagnostics. 2025. https:\/\/doi.org\/10.3390\/diagnostics15030252.","journal-title":"Diagnostics"},{"issue":"1","key":"4182_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jncc.2024.06.007","volume":"5","author":"C-N Zhao","year":"2025","unstructured":"Zhao C-N, Chiang C-L, Chiu W-HK, Chan S-KK, Li C-BJ, Chen W-W, et al. Treatments of transarterial chemoembolization (TACE), stereotactic body radiotherapy (SBRT) and immunotherapy reshape the systemic tumor immune environment (STIE) in patients with unresectable hepatocellular carcinoma. J Natl Cancer Cent. 2025;5(1):38\u201349. https:\/\/doi.org\/10.1016\/j.jncc.2024.06.007.","journal-title":"J Natl Cancer Cent"},{"key":"4182_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/jhc.S286213","volume":"8","author":"S Li","year":"2021","unstructured":"Li S, Xu W, Liao M, Zhou Y, Weng J, Ren L, et al. The significance of gamma-glutamyl transpeptidase to lymphocyte count ratio in the early postoperative recurrence monitoring and prognosis prediction of AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:23\u201333. https:\/\/doi.org\/10.2147\/jhc.S286213.","journal-title":"J Hepatocell Carcinoma"},{"key":"4182_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1178123","author":"W Zhang","year":"2023","unstructured":"Zhang W, Bi Y, Yang K, Xie Y, Li Z, Yu X, et al. A new model based on gamma-glutamyl transpeptidase to lymphocyte ratio and systemic immune-inflammation index can effectively predict the recurrence of hepatocellular carcinoma after liver transplantation. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1178123.","journal-title":"Front Oncol"},{"issue":"2","key":"4182_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12029-022-00832-0","volume":"54","author":"G Mishra","year":"2022","unstructured":"Mishra G, Majeed A, Dev A, Eslick GD, Pinato DJ, Izumoto H, et al. Clinical utility of albumin bilirubin grade as a prognostic marker in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a systematic review and meta-analysis. J Gastrointest Cancer. 2022;54(2):420\u201332. https:\/\/doi.org\/10.1007\/s12029-022-00832-0.","journal-title":"J Gastrointest Cancer"},{"issue":"15","key":"4182_CR35","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.7150\/jca.29499","volume":"10","author":"W Zhang","year":"2019","unstructured":"Zhang W, Zhangyuan G, Wang F, Zhang H, Yu D, Wang J, et al. High preoperative serum globulin in hepatocellular carcinoma is a risk factor for poor survival. J Cancer. 2019;10(15):3494\u2013500. https:\/\/doi.org\/10.7150\/jca.29499.","journal-title":"J Cancer"},{"key":"4182_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1067353","author":"X-Y Ge","year":"2023","unstructured":"Ge X-Y, Sun M-C, Wang T-Y, Wang X-M, Liu G, Yang T, et al. Analysis of risk factors of hepatocellular carcinoma and establishment of a clinical prognosis model. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1067353.","journal-title":"Front Oncol"},{"issue":"5","key":"4182_CR37","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/s1470-2045(19)30149-4","volume":"20","author":"KY Ngiam","year":"2019","unstructured":"Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. Lancet Oncol. 2019;20(5):e262\u201373. https:\/\/doi.org\/10.1016\/s1470-2045(19)30149-4.","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04182-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04182-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04182-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:53:55Z","timestamp":1770123235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04182-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4182"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04182-6","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}